

CONTENT

1. INTRODUCTION	1-14
1.1. Hemostasis and thrombosis	1
1.2. Blood coagulation.....	2
1.3. Conventional antithrombotic therapy	4
1.4. FXa as a promising target for the development of antithrombotic drugs	8
1.5. FXa: structural analysis	10
1.6. Structural difference between FXa and Thrombin	12
2. LITERATURE REVIEW.....	15-28
2.1. Development of direct FXa inhibitors.....	15
2.2. Early prototype molecules for the development of direct FXa inhibitors	15
2.3. Approaches for the discovery of oral FXa inhibitors	17
2.3.1. Covalent inhibitors: Peptidomimetics and transition state analogs....	17
2.3.2. Early dibasic benzamidine approach.....	18
2.4. Transition from benzamidine to oral agents	19
2.4.1. Pyrrolidine based FXa inhibitors.....	19
2.4.2. Oxazolidinone and isoxazole based FXa inhibitors	21
2.4.3. Pyrazole based FXa inhibitors.....	22
2.4.4. Tetrahydroisoquinolines as FXa inhibitors.....	23
2.4.5. Arylsulfonamidopiperidone derivatives	24
2.4.6. Anthranilamides and disubstituted benzenes as FXa inhibitors	25
2.4.7. 2,3-Dihydroquinazolin-4(<i>IH</i>)-one derivatives	27
3. AIMS AND OBJECTIVES	29-32
4. RESULTS AND DISCUSSION.....	33-126
4.1. 2-Aminobenzamide-based Factor Xa Inhibitors	33
4.1.1. Designing of 2-Aminobenzamide-based Factor Xa Inhibitors.....	33

4.1.2. Synthesis of the designed 2-aminobenzamide derivatives	34
4.1.2.1. Synthesis of <i>N</i> -substituted isatoic anhydride (52-63).....	34
4.1.2.2. Synthesis of substituted 2-amino- <i>N</i> -(5-chloropyridin-2-yl)benzamide (64-76).....	36
4.1.2.3. Synthesis of 2-(2-chloroacetamido)- <i>N</i> -(5-chloropyridin-2-yl)benzamide (77)	43
4.1.2.4. 2-(2-(<i>N</i> -Substituted piperazin-1-yl)acetamido)- <i>N</i> -(5-chloropyridin-2-yl)benzamide (78-83)	44
4.1.2.5. Synthesis of substituted 4-bromomethyl-1,1'-biphenyls (93-101)..	49
4.1.2.6. Synthesis of 2-(4-(2-/3-/4-substituted phenyl)benzylamino)- <i>N</i> -(5-chloropyridin-2-yl)benzamide (102-110)	49
4.1.3. Biological evaluation.....	56
4.1.3.1. <i>In vitro</i> FXa and thrombin inhibition assays	56
4.1.3.2. <i>Ex vivo</i> PT prolongation and clotting time	58
4.1.3.3. <i>In vivo</i> FeCl ₃ induced arterial thrombosis	59
4.1.4. Molecular modeling studies	60
4.1.4.1. Docking studies	60
4.1.4.2. Molecular dynamics simulations.....	63
4.2. 1,3,4-Thiadiazole-based FXa inhibitors.....	65
4.2.1. Designing of 1,3,4-thiadiazole derivatives as FXa inhibitors	65
4.2.2. Synthesis of 1,3,4-thiadiazole derivatives	69
4.2.2.1. Synthesis of thiosemicarbazide derivatives (126-140) and 5-substituted amino-1,3,4-thiadiazole-2-thiols (141-155).....	69
4.2.2.2. Synthesis of lead molecule (158)	72
4.2.2.3. Synthesis of 5-(substituted-benzylthio)- <i>N</i> -(4-chlorophenyl)-1,3,4-thiadiazol-2-amines (159-165)	74
4.2.2.4. Synthesis of 5-(thiosubstituted)- <i>N</i> -(4-chlorophenyl)-1,3,4-thiadiazol-2-amines (178-186)	77

4.2.2.5. Synthesis of substituted anilines (197-204, 208, 210).....	82
4.2.2.6. Synthesis of 2-((5-((4-chlorophenyl)amino)-1,3,4-thiadiazol-2-yl)thio)- <i>N</i> -phenylacetamides (227-239)	85
4.2.2.7. Synthesis of 2-((5-(substituted phenyl or benzylamino)-1,3,4-thiadiazol-2-yl)thio)- <i>N</i> -(4-(2-oxopyridin-1(2 <i>H</i>)-yl)phenyl)acetamides (240-253).....	93
4.2.3. Biological evaluation.....	101
4.2.3.1. <i>In vitro</i> FXa inhibition assay	101
4.2.3.2. <i>In vitro</i> anticoagulant activity.....	102
4.2.3.3. <i>In vivo</i> FeCl ₃ induced arterial thrombosis	107
4.2.4. Molecular modeling studies	108
4.2.4.1. Docking studies of compound (237)	108
4.2.4.2. Molecular Dynamics Simulations	109
4.3. Carbazole derivatives as FXa inhibitors	111
4.3.1. Designing of carbazole derivatives as FXa inhibitors.....	111
4.3.2. Synthesis of carbazole derivatives	114
4.3.2.1. Synthesis of 9-(4-chlorobenzyl)-9 <i>H</i> -carbazole-3-carboxylic acid (263)	114
4.3.2.2. Synthesis of necessary aromatic amines (194-201, 205, 266, 267, 270).....	117
4.3.2.3. Synthesis of 9-(4-chlorobenzyl)- <i>N</i> -substituted-9 <i>H</i> -carbazole-3-carboxamides (271-282).....	117
4.3.3. Biological evaluation of the synthesized compounds (271-282)	125
4.3.3.1. <i>In vitro</i> anticoagulant activity.....	125
4.3.3.2. <i>In vitro</i> FXa inhibition assay for evaluation of antithrombotic activity.....	125
5. EXPERIMENTAL	127-224
5.1. Chemical studies	127

5.1.1. 2-Aminobenzamide-based FXa Inhibitors	128
5.1.1.1. General method for the synthesis of <i>N</i> -substituted isatoic anhydride (52-63)	128
5.1.1.2. General method for the synthesis of substituted 2-amino- <i>N</i> -(5-chloropyridin-2-yl)benzamides (64-76)	132
5.1.1.3. Synthesis of 2-(2-chloroacetamido)- <i>N</i> -(5-chloropyridin-2-yl)benzamide (77)	139
5.1.1.4. General method for the synthesis of 2-(2-(<i>N</i> -Substituted piperazin-1-yl)acetamido)- <i>N</i> -(5-chloropyridin-2-yl)benzamides (78-83).....	140
5.1.1.5. General method for the synthesis of substituted 4-bromomethyl-1,1'-biphenyls (93-101).....	144
5.1.1.6. General method for the synthesis of 2-(4-(2- or 4-substituted phenyl)benzylamino)- <i>N</i> -(5-chloropyridin-2-yl)benzamides (102-110)	145
5.1.2. 1,3,4-Thiadiazole-based FXa inhibitors.....	151
5.1.2.1. Designing of 1,3,4-thiadiazole derivatives as FXa inhibitors	151
5.1.2.2. Synthesis of designed 1,3,4-thiadiazole derivatives.....	154
5.1.2.2.1. Synthetic methods for the synthesis of thiosemicarbazide derivatives (126-140)	154
5.1.2.2.2. General synthetic method for the synthesis of 5-(substituted amino)-1,3,4-thiadiazole-2-thiols (141-155)	159
5.1.2.2.3. Synthesis of lead molecule (158)	164
5.1.2.2.4. Synthesis of 5-(substituted-benzylthio)- <i>N</i> -(4-chlorophenyl)-1,3,4-thiadiazol-2-amines (159-165)	166
5.1.2.2.5. Synthesis of amidoalkyls (169-177).....	170
5.1.2.2.6. Synthesis of 5-(thiosubstituted)- <i>N</i> -(4-chlorophenyl)-1,3,4-thiadiazol-2-amines (178-186)	171
5.1.2.2.7. Synthesis of substituted anilines (197-204, 208, 210).....	176
5.1.2.2.7.1. General methods for the synthesis of substituted nitro compounds (189-196).....	176

5.1.2.2.7.2. General procedure for the synthesis of compounds (197-204, 208).....	179
5.1.2.2.7.3. General method for the synthesis of substituted <i>N</i> -phenylacetamides (214-226)	183
5.1.2.2.8. 2-((5-((4-Chlorophenyl)amino)-1,3,4-thiadiazol-2-yl)thio)- <i>N</i> -phenylacetamides (227-239)	187
5.1.2.2.9. Synthesis of 2-((5-(substituted phenylamino or benzylamino)-1,3,4-thiadiazol-2-yl)thio)- <i>N</i> -(4-(2-oxopyridin-1(2 <i>H</i>)-yl)phenyl)acetamides (240-253).....	196
5.1.3. Carbazole derivatives as FXa inhibitors	206
5.1.3.1. Synthesis of the designed carbazole derivatives	206
5.1.3.1.1. 9-(4-Chlorobenzyl)-9 <i>H</i> -carbazole (261)	206
5.1.3.1.2. 9-(4-Chlorobenzyl)-9 <i>H</i> -carbazole-3-carbaldehyde (262)	207
5.1.3.1.3. 9-(4-Chlorobenzyl)-9 <i>H</i> -carbazole-3-carboxylic acid (263)	208
5.1.3.1.4. Synthesis of necessary aromatic amines (197-204, 208, 264, 265, 268).....	208
5.1.3.1.5. General method for the synthesis of 9-(4-chlorobenzyl)- <i>N</i> -substituted-9 <i>H</i> -carbazole-3-carboxamides (271-282).....	210
5.2. Biological evaluation	219
5.2.1. <i>In vitro</i> FXa and thrombin inhibition assays	219
5.2.2. Thrombin inhibition studies	220
5.2.3. <i>Ex vivo</i> PT prolongation	220
5.2.4. Whole blood clotting time	220
5.2.5. <i>In vitro</i> anticoagulant activity.....	221
5.2.6. <i>In vivo</i> FeCl ₃ induced arterial thrombosis	221
5.3. Computational studies	222
5.3.1. Docking studies of compounds (107 and 237) with FXa enzyme ...	222
5.3.2. Molecular dynamics simulations.....	223

6. CONCLUSION	225-226
REFERENCES.....	227-244
SUPPLEMENTARY MATERIAL	S1-S18